Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.
Recombinant human insulin-like growth factor I (rhIGF-I) was infused subcutaneously into hypophysectomized rats for as long as 18 days. Three hundred micrograms (39 nmol) of rhIGF-I per day and 200 milliunits (4.5 nmol) of human growth hormone (hGH) per day increased body weight, tibial epiphyseal width, longitudinal bone growth, and trabecular bone formation similarly. Weight gains of the kidneys and spleen, however, were greater with rhIGF-I than with hGH, whereas the weight of the epididymal fat pads was reduced with rhIGF-I. The weight of the thymus was increased by rhIGF-I treatment. Thus, IGF-I administered over a prolonged period of time mimics GH effects in hypophysectomized rats. Quantitative differences between rhIGF-I and hGH treatment with respect to organ weights may be related to different forms of circulating IGF-I or may be due to independent effects of GH and IGF-I. The results support the somatomedin hypothesis, but they also stress the role of GH as a modulator of IGF-I action.
Guler
H P
HP
Metabolic Unit, University Hospital, Zürich, Switzerland.
Zapf
J
J
Scheiwiller
E
E
Froesch
E R
ER
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D007016:Hypophysectomy; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D008297:Male; D009929:Organ Size / Q000187:drug effects*; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D013002:Somatomedins / Q000494:pharmacology* / Q000502:physiology
D011994:Recombinant Proteins; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I